Green Cross received approval for the Phase II clinical trial of 'Hepabig-gene' from Ministry of Food and Drug Safety
On August 27, Green Cross announced that they received approval for the Phase II test plan of 'Hepabig-gene' which is gene recombinant hepatitis B immune globulin from Ministry of Food and Drug Safety.
'Hepabig-gene' is gene recombination method hepatitis B antibody treatment (Bio new drug). 'H...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
